Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study

PLoS One. 2013;8(1):e52755. doi: 10.1371/journal.pone.0052755. Epub 2013 Jan 11.

Abstract

Background: Numerous studies have looked at the potential benefits of various nootropic drugs such as Ginkgo biloba extract (EGb761®; Tanakan®) and piracetam (Nootropyl®) on age-related cognitive decline often leading to inconclusive results due to small sample sizes or insufficient follow-up duration. The present study assesses the association between intake of EGb761® and cognitive function of elderly adults over a 20-year period.

Methods and findings: The data were gathered from the prospective community-based cohort study 'Paquid'. Within the study sample of 3612 non-demented participants aged 65 and over at baseline, three groups were compared: 589 subjects reporting use of EGb761® at at least one of the ten assessment visits, 149 subjects reporting use of piracetam at one of the assessment visits and 2874 subjects not reporting use of either EGb761® or piracetam. Decline on MMSE, verbal fluency and visual memory over the 20-year follow-up was analysed with a multivariate mixed linear effects model. A significant difference in MMSE decline over the 20-year follow-up was observed in the EGb761® and piracetam treatment groups compared to the 'neither treatment' group. These effects were in opposite directions: the EGb761® group declined less rapidly than the 'neither treatment' group, whereas the piracetam group declined more rapidly (β = -0.6). Regarding verbal fluency and visual memory, no difference was observed between the EGb761® group and the 'neither treatment' group (respectively, β = 0.21 and β = -0.03), whereas the piracetam group declined more rapidly (respectively, β = -1.40 and β = -0.44). When comparing the EGb761® and piracetam groups directly, a different decline was observed for the three tests (respectively β = -1.07, β = -1.61 and β = -0.41).

Conclusion: Cognitive decline in a non-demented elderly population was lower in subjects who reported using EGb761® than in those who did not. This effect may be a specific medication effect of EGb761®, since it was not observed for another nootropic medication, piracetam.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / psychology
  • Female
  • Follow-Up Studies
  • Ginkgo biloba / chemistry*
  • Humans
  • Logistic Models
  • Male
  • Nootropic Agents / administration & dosage
  • Nootropic Agents / pharmacology
  • Piracetam / administration & dosage
  • Piracetam / pharmacology*
  • Plant Extracts / administration & dosage
  • Plant Extracts / pharmacology*
  • Population Surveillance / methods
  • Prospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Nootropic Agents
  • Plant Extracts
  • Ginkgo biloba extract
  • Piracetam

Grants and funding

The PAQUID study was supported by ARMA (Bordeaux); Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (CNAMTS); Conseil Général de la Dordogne; Conseil Général de la Gironde; Conseil Régional d'Aquitaine; Fondation de France; France Alzheimer (Paris); GIS Longévité; Institut National de la Santé et de la Recherche Médicale (INSERM); Mutuelle Générale de l'Education Nationale (MGEN); Mutualité Sociale Agricole (MSA); NOVARTIS Pharma (France); SCOR Insurance (France). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.